Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Total 13F shares
-
49,867,878
-
Share change
-
+1,184,630
-
Total reported value
-
$1,216,503,031
-
Put/Call ratio
-
20%
-
Price per share
-
$24.42
-
Number of holders
-
135
-
Value change
-
+$35,616,766
-
Number of buys
-
87
-
Number of sells
-
40
Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q2 2020
As of 30 Jun 2020 Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) had 135 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 49,867,878 shares of stock of the company.
Largest 10 holders included BlackRock Inc., JPMORGAN CHASE & CO, WELLINGTON MANAGEMENT GROUP LLP, ArrowMark Colorado Holdings LLC, FRANKLIN RESOURCES INC, Essex Woodlands Management, Inc., VANGUARD GROUP INC, ALLIANCEBERNSTEIN L.P., Capital World Investors, and JENNISON ASSOCIATES LLC.
This table shows 136 institutional shareholders of the security as of 30 Jun 2020.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.